1-4 of 4
A. Dimitrios Colevas
Close
Sort by
Journal Articles

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
John C. Byrd, Thomas S. Lin, James T. Dalton, Di Wu, Mitch A. Phelps, Beth Fischer, Mollie Moran, Kristie A. Blum, Brad Rovin, Michelle Brooker-McEldowney, Sarah Broering, Larry J. Schaaf, Amy J. Johnson, David M. Lucas, Nyla A. Heerema, Gerard Lozanski, Donn C. Young, Jose-Ramon Suarez, A. Dimitrios Colevas, Michael R. Grever
Journal: Blood
Blood (2006) 109 (2): 399–404.
https://doi.org/10.1182/blood-2006-05-020735
Published: 2006
Journal Articles

Phase II Clinical Trial of Flavopiridol (FL) Followed by ara-c and Mitoxantrone (AM) for Adults with Relapsed and Refractory Acute Leukemias.

Judith E. Karp, MD, B. Douglas Smith, MD, Jacqueline Greer, R.N., Janet Briel, R.N., Mark J. Levis, MD/PhD, Michael A. McDevitt, MD/PhD, Steven D. Gore, MD, A. Dimitrios Colevas, MD
Journal: Blood
Blood (2005) 106 (11): 2784.
https://doi.org/10.1182/blood.V106.11.2784.2784
Published: 2005
Journal Articles

Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.

Steven Grant, Daniel Sullivan, David Roodman, Robert Stuart, Edward B. Perkins, Viswanathan Ramakrishnan, John Wright, A. Dimitrios Colevas, John D. Roberts
Journal: Blood
Blood (2005) 106 (11): 3338.
https://doi.org/10.1182/blood.V106.11.3338.3338
Published: 2005
Journal Articles

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.

Steven Grant, Judith E. Karp, Omer N. Koc, Brenda Cooper, Selina Luger, William D. Figg, Merrill Egorin, Brian J. Druker, James W. Jacobberger, Viswanathan Ramakrishnan, Edward B. Perkins, A. Dimitrios Colevas, John D. Roberts
Journal: Blood
Blood (2005) 106 (11): 1102.
https://doi.org/10.1182/blood.V106.11.1102.1102
Published: 2005